Printer Friendly

Jazz Pharmaceuticals submits Solriamfetol NDA with US FDA for narcolepsy or obstructive sleep apnea.

M2 EQUITYBITES-March 5, 2018-Jazz Pharmaceuticals submits Solriamfetol NDA with US FDA for narcolepsy or obstructive sleep apnea

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Biopharmaceutical company Jazz Pharmaceuticals plc (Nasdaq:JAZZ) said on Friday that it has successfully filed its New Drug Application (NDA) with the US Food and Drug Administration (FDA ) seeking marketing approval for solriamfetol for the treatment of obstructive sleep apnea (OSA).

In conjunction, the Prescription Drug User Fee Act (PDUFA) goal date for solriamfetol for an US FDA decision is 20 December 2018, added the company.

Jazz Pharmaceuticals said solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) in development for the treatment of excessive sleepiness in adult patients with narcolepsy, OSA, and Parkinson's disease.

The company added that solriamfetol Phase 3 clinical programme includes one study evaluating excessive sleepiness in adult patients with narcolepsy (TONES 2), two studies evaluating excessive sleepiness in adult patients with OSA (TONES 3 and TONES 4), and an open-label, long-term safety and maintenance of efficacy study (TONES 5) in the treatment of excessive sleepiness in patients with narcolepsy or OSA.

OSA is a prevalent disease (as high as 14% in men and 5% in women) with excessive sleepiness being a major presenting complaint in many cases. Excessive sleepiness in OSA is associated with impairments in cognitive function, safety, productivity, interpersonal relationships and overall quality of life. Narcolepsy is a debilitating neurological disorder characterized by excessive sleepiness and the inability to regulate sleep-wake cycles normally.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Mar 5, 2018
Words:258
Previous Article:Regal Beloit Expands Product Lineup with Acquisition of Italy Based Nicotra Gebhardt.
Next Article:Autoliv adds two new directors to board.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters